Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:
PRPO) is pleased to welcome Christina Valauri to its board of
directors effective Jan 1st, 2024. Ms. Valauri is joining
Precipio’s board to support management’s understanding of and
interaction with the capital markets, as we look towards 2024 to be
an important period for our company from both a business growth,
and financial perspective.
Ms. Valauri brings a
30-year proven track record as a senior healthcare analyst and has
held leadership roles that include US and Global Head of Equity
Research and Managing Director at Cantor Fitzgerald, and senior
equity research management roles at firms including ING, Credit
Lyonnais (acquired by Credit Agricole), and Natixis. She has been
recognized by The Wall Street Journal’s “Best on The Street”
All-Star Analyst Survey and has received the Award for Excellence
in Medical Education Public Affairs - Association of American
Medical Colleges.
Ms. Valauri is the
founding partner and CEO of Sagestone Advisory, LLC. Her background
in equity securities research has provided a deep base of
experience in pharmaceutical, biotech, and med-tech companies. She
has extensive experience identifying and analyzing the commercial
potential of breakthrough innovations, as well as mentoring and
advising C-suite teams of private and public early-stage healthcare
companies through product development, regulatory, go-to-market
strategies, potential mergers and acquisitions, and IPOs.
Ms. Valauri currently
serves as an Entrepreneur In Residence at Weill Cornell Medicine
BioVenture eLab where she applies her skills and experience in life
sciences and business to support the organization’s mission to
foster an entrepreneurial ecosystem related to the innovations of
researchers, and clinicians. Ms. Valauri earned her BA in Biology
from Reed College and an MBA from Cornell University.
“As we continue to
execute on our goals, and increase our interaction with the public
markets, it's incredibly helpful to have someone like Christina who
knows what the investor audiences are looking to see in an early
stage growth company,” said Ilan Danieli, Precipio’s CEO, “In the
few months that I have had the pleasure of getting to know
Christina, she has already dramatically contributed to our
knowledge and understanding of what drives the conversion of a
company’s business success to an increase in shareholder value. We
are fortunate to have her join our board.”
After serving on
Precipio’s board of directors for 6 years, Douglas Fisher, MD is
stepping off the board to maintain a board of 7 directors and will
remain as an observer moving forward.
“Although Doug is
formally stepping down as a director, I am delighted that our
relationship with him is not ending,” said Ilan Danieli, CEO. “Doug
has played an integral role in the company’s leadership; his
combination of medicine and business education, and his experience
in early stage and public companies has and will continue to be
invaluable to the company.”
“I’m excited about
Precipio’s prospects moving forward, and Ms. Valauri brings
excellent experience to help accelerate our interactions with
public market investors. I’m looking forward to continuing to
support the company moving forward,” said Doug Fisher, MD.
About Precipio
Precipio is a healthcare biotechnology company
focused on cancer diagnostics. Our mission is to address the
pervasive problem of cancer misdiagnoses by developing solutions in
the form of diagnostic products and services. Our products and
services deliver higher accuracy, improved laboratory workflow, and
ultimately deliver better patient outcomes which reduce healthcare
expenses. Precipio develops innovative technologies in our clinical
laboratory where we design, test, validate, and run these products
intended to improve diagnostic outcomes. Precipio then
commercializes its technologies as proprietary products that serve
the global laboratory community and further scales Precipio’s reach
to eradicate misdiagnosis. For more information, please visit
www.precipiodx.com.
Please follow us on LinkedIn, X@PrecipioDx
and Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including, without
limitation, statements regarding the targets set herein and related
timing.
Except for historical information, statements
about future volumes, sales, growth, costs, cost savings, margins,
earnings, earnings per share, diluted earnings per share, cash
flows, plans, objectives, expectations, growth or profitability are
forward-looking statements based on management’s estimates,
beliefs, assumptions and projections. Words such as “could,” “may,”
“expects,” “anticipates,” “will,” “targets,” “goals,” “projects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,”
and variations on such words, and similar expressions that reflect
our current views with respect to future events and operational,
economic and financial performance, are intended to identify such
forward-looking statements. These forward-looking statements are
only predictions based on management’s current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the important factors
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2022 and our other
reports filed with the U.S. Securities and Exchange Commission. Any
such forward-looking statements represent management’s estimates as
of the date of this press release only. While we may elect to
update such forward-looking statements at some point in the future,
except as required by law, we disclaim any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Jul 2023 to Jul 2024